Wolfe Research Adjusts Eli Lilly Price Target to $1,100 From $1,000, Keeps Outperform Rating
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $989
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $900
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $928
Eli Lilly Analyst Ratings
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,124
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Eli Lilly Is Maintained at Overweight by Morgan Stanley
Eli Lilly Analyst Ratings
Eli Lilly & Co (LLY) Gets a Buy From Bank of America Securities
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,190
Eli Lilly Analyst Ratings
Eli Lilly Assumed With Buy From Neutral at Goldman Sachs
Goldman Sachs Initiates Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $888
Eli Lilly & Co: Strategic Global Expansion and R&D Commitment Drive Buy Rating
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,190
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,050
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,190